or Try an Advanced Search...

    Technical Analysis for CRBP - Corbus Pharmaceuticals Holdings, Inc.

    Grade Last Price % Change Price Change
    F 16.75 4.17% 0.67
    CRBP closed down 2.9 percent on Wednesday, November 20, 2024, on 33 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CRBP trend table...
    Date Alert Name Type % Chg
    Oversold Stochastic Weakness 4.17%
    NR7 Range Contraction 1.15%
    NR7-2 Range Contraction 1.15%
    Stochastic Reached Oversold Weakness 1.15%
    Gapped Down Weakness 1.15%
    Oversold Stochastic Weakness 1.15%
    NR7 Range Contraction -0.06%
    Fell Below 20 DMA Bearish 0.84%
    20 DMA Support Bullish -4.56%
    NR7 Range Contraction -4.56%
    Older End-of-Day Signals for CRBP ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 2 hours ago
    Up 3% about 2 hours ago
    Rose Above Previous Day's High about 3 hours ago
    Up 2% about 3 hours ago
    Up 1% about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRBP Chart by TradingView
    Basic chart:

    Profile

    Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel therapeutics to treat inflammatory-fibrotic diseases. The company primarily develops Resunab, an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and diffuse scleroderma. It sells its products through hearing professionals, including audiologists, hearing aid specialists, and ENT doctors worldwide. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Hearing Cystic Fibrosis Hearing Aid Fibrotic Disease Treatment Of Cystic Fibrosis Ajulemic Acid Channelopathies Scleroderma

    Is CRBP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 21 Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
    Nov 12 Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
    Nov 11 Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
    Nov 9 We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
    Nov 7 Corbus Pharmaceuticals: Q3 Earnings Snapshot
    Nov 7 Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
    Nov 4 Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
    Nov 4 Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
    Oct 29 Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
    Oct 16 Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
    See more CRBP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 61.9
    52 Week Low 4.0
    Average Volume 778,133
    200-Day Moving Average 38.88
    50-Day Moving Average 22.39
    20-Day Moving Average 17.34
    10-Day Moving Average 17.56
    Average True Range 1.36
    RSI (14) 32.43
    ADX 27.86
    +DI 15.84
    -DI 28.03
    Chandelier Exit (Long, 3 ATRs) 16.69
    Chandelier Exit (Short, 3 ATRs) 19.73
    Upper Bollinger Bands 19.46
    Lower Bollinger Band 15.22
    Percent B (%b) 0.2
    BandWidth 24.43
    MACD Line -1.57
    MACD Signal Line -1.93
    MACD Histogram 0.3624
    Fundamentals Value
    Market Cap 166.22 Million
    Num Shares 10.3 Million
    EPS -11.12
    Price-to-Earnings (P/E) Ratio -1.45
    Price-to-Sales 163.32
    Price-to-Book 744.81
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.32
    Resistance 3 (R3) 17.32 16.90 17.11
    Resistance 2 (R2) 16.90 16.58 16.90 17.05
    Resistance 1 (R1) 16.49 16.39 16.28 16.49 16.98
    Pivot Point 16.07 16.07 15.96 16.07 16.07
    Support 1 (S1) 15.66 15.75 15.45 15.67 15.18
    Support 2 (S2) 15.24 15.56 15.24 15.11
    Support 3 (S3) 14.83 15.24 15.05
    Support 4 (S4) 14.84